- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Mesoblast Acquires CAR Platform License From Mayo
Rights came via a Mayo-linked startup, and Mayo will provide GMP support. Mesoblast sees near-term use in ulcerative colitis, Crohn's and lupus.
Apr. 15, 2026 at 12:10am
Got story updates? Submit your updates here. ›
Mesoblast's acquisition of a pioneering CAR technology platform aims to elevate the precision and potency of its allogeneic cell therapies for inflammatory diseases.NYC TodayMesoblast Limited, a global leader in allogeneic cellular medicines for inflammatory diseases, has acquired an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform for precision-enhanced augmentation of therapeutic mesenchymal lineage stromal cell (MSC) products. Mesoblast plans to incorporate the engineered CARs to further boost the effectiveness of its products, with the goal of enhancing target specificity and augmenting inherent properties of immunomodulation and tissue regeneration.
Why it matters
This acquisition allows Mesoblast to leverage the CAR technology developed at Mayo Clinic to create even more potent cell therapy products for treating inflammatory and autoimmune diseases like ulcerative colitis, Crohn's disease, and lupus nephritis. The ability to precisely target inflamed tissues and enhance the immunomodulatory effects of Mesoblast's MSC-based therapies could lead to significant improvements in patient outcomes.
The details
The foundational work on the CAR technology was developed by investigators at Mayo Clinic and published in Nature Biomedical Engineering. The investigators identified various CAR-MSCs with potential for enhanced tissue-specific targeting in inflammatory and autoimmune diseases, including to inflamed bowel. Mesoblast obtained the worldwide exclusive rights to the CAR-MSC intellectual property through the acquisition of a startup formed specifically to advance the technology. As part of the exclusive license, Mayo Clinic will provide in-kind support geared toward further advancing the technology and resulting products, including GMP manufacturing activities.
- Mesoblast announced the acquisition on April 14, 2026.
The players
Mesoblast Limited
A global leader in allogeneic cellular medicines for inflammatory diseases.
Mayo Clinic
A not-for-profit organization committed to clinical practice, education and research, which developed the foundational CAR technology licensed to Mesoblast.
What they’re saying
“This innovative genetic modification technology fits well with our strategy to extend our market leadership by creating products with even greater efficacy and new target indications.”
— Silviu Itescu, Chief Executive of Mesoblast
What’s next
Mesoblast plans to use the licensed CAR technology to generate products with enhanced potency for treating inflammatory bowel diseases like ulcerative colitis and Crohn's disease, as well as B cell autoimmune diseases like lupus nephritis.
The takeaway
This acquisition allows Mesoblast to further strengthen its position as a leader in allogeneic cellular therapies by leveraging innovative CAR technology to create even more effective treatments for severe inflammatory and autoimmune conditions. The collaboration with Mayo Clinic provides valuable expertise and support to advance this new platform.
